The Discharge Companion Program: An Interprofessional Collaboration in Transitional Care Model Delivery.
Jennifer M BinghamPatrick CampbellKate SchusselAnn M TaylorKevin BoesenAmanda HarringtonSandra LealTerri WarholakPublished in: Pharmacy (Basel, Switzerland) (2019)
To reduce readmission rates and avoid financial penalties from the Centers for Medicare and Medicaid Services, hospitals are seeking to implement innovative transitions of care (TOC) programs. This retrospective study evaluated the Discharge Companion Program (DCP), a pharmacist- and nurse-coordinated interprofessional, collaborative TOC program. Adult patients (18 years and older) from a single hospital, discharged with at least one qualifying diagnosis, were eligible for this service. The hospital transitional care coordinator nurse referred qualified patients to the DCP nurse coordinator, who scheduled telephonic medication therapy management (MTM) reviews with the DCP pharmacist at one- and three-weeks postdischarge. Hospital records and DCP documentation were reviewed to describe respective interventions and assess the impact on 30-day readmissions. A total of 456 patients were referred to the DCP between 31 August, 2015 and 7 September, 2016. Of the 340 patients who participated (DCP group), 44 (13%) compared to 17% (n = 20) of the usual care, were readmitted within 30-days postdischarge. The DCP pharmacists conducted 1242 clinical interventions with participants, demonstrating the benefits of an interprofessional TOC model involving multiple, pharmacist-delivered MTM intervention touchpoints within 30 days post-hospital discharge.
Keyphrases
- healthcare
- quality improvement
- affordable care act
- patient safety
- end stage renal disease
- palliative care
- primary care
- ejection fraction
- newly diagnosed
- randomized controlled trial
- mental health
- peritoneal dialysis
- physical activity
- prognostic factors
- adverse drug
- emergency department
- systematic review
- public health
- health insurance
- middle aged
- young adults
- general practice
- mesenchymal stem cells
- gestational age